Skip to content

Efficacy of transcutaneous auricular vagus nerve stimulation in the treatment of AIDS with depression symptoms

Efficacy of transcutaneous auricular vagus nerve stimulation in the treatment of AIDS with depression symptoms

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074306
Enrollment
Unknown
Registered
2023-08-03
Start date
2023-08-15
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS with depressive symptoms

Interventions

Treatment group:ART conventional treatment and transcutaneous auricular vagus nerve stimulation
Control group:ART conventional treatment and transcutaneous non-vagus nerve stimulation

Sponsors

Institute of acupuncture and moxibustion, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria; 2. Being HIV positive and confirmed by a Western Blot report confirmatory test; 3. Patients aged between 18-70 years, male or female; 4. 24 >= points >= 7 on the 17-item Hamilton Depression Scale (17-HAMD); suicidal ideation excluded, with all responses on the Suicide Severity Scale being "no" and a score of < 3 on item 3 of the HAMD-17 (suicide item); 5. On ART for more than 2 years, with a plasma HIV load of less than 50 copies/ml for more than 1.5 years; 6. CD4+ T lymphocyte level < 200 cells/ul or an increase of < 20% compared to treatment baseline; 7. Patients voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with severe opportunistic infections that were not controlled prior to enrollment; 2.Patients who were enrolled in a clinical trial of another drug within 1 month prior to enrollment or are currently enrolled in a clinical trial of another drug; patients who have met DSM-V criteria for substance-related and addictive disorders within the past 6 months; 3. Patients who were receiving any other antidepressant medication prior to enrolment; 4. WBC = 2 times the upper limit of the reference value, abnormal renal function means creatinine clearance below normal); 5. Patients with a history of schizophrenia or other psychiatric disorders; patients with cognitive impairment or personality disorders; 6. Women who are pregnant or breastfeeding, or planning to become pregnant; 7. In combination with other serious diseases (e.g. tumours, cirrhosis of the liver, cardiovascular disease, etc.); 8. Patients with an intellectual or language impairment that prevents them from fully understanding the test or cooperating well. Those who meet the inclusion criteria but have one of the above conditions will be excluded.

Design outcomes

Primary

MeasureTime frame
17-HAMD (Hamilton Depression Rating Scale);

Secondary

MeasureTime frame
14-HAMA (Hamilton Anxiety Scale);WHO-HIV Quality of Survival Scale score;Heart rate variability(HRV);

Countries

China

Contacts

Public ContactLi Shaoyuan

Institute of acupuncture and moxibustion, China Academy of Chinese Medical Sciences

704488328@qq.com+86 159 0149 8725

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026